Exelixis Inc Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
Exelixis Inc (EXEL) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $1.73 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2012-02-22
- Exelixis Inc proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2011-12-31 was $747.00K, a 26.04% decline year-over-year.
- Exelixis Inc proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2011-09-30 was $0.00.
- Exelixis Inc proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2010-12-31 was $1.01M.
- Exelixis Inc proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2010-09-30 was $0.00.
- Exelixis Inc proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2011 was $1.73M, a 44.64% decline from fiscal 2010.
- Exelixis Inc proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2010 was $3.13M, a 18.14% decline from fiscal 2009.
- Exelixis Inc proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2009 was $3.83M.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2011-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $747.00K derived: sum of 2 quarters · filed 2012-02-22 | $1.73M 10-K · filed 2012-02-22 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $987.00K 10-Q · filed 2011-10-27 | ||
| 2011-06-30 | $987.00K 10-Q · filed 2011-08-04 | |||
| 2010-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $1.01M derived: sum of 2 quarters · filed 2012-02-22 | $3.13M 10-K · filed 2012-02-22 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $2.12M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $2.12M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $3.83M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |